ESMO 2019 | FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Arndt Vogel • 29 Sep 2019

Bile Duct Cancer Gastrointestinal Cancer Pemigatinib

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the FIGHT-202 study (EudraCT: 2016-002422-36) of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC

Arndt Vogel • 11 Jun 2021

Treatment landscape for HCC

Arndt Vogel • 9 Nov 2018

RATIONALE-301: elderly subgroup analysis of tislelizumab in HCC

Arndt Vogel • 3 Jul 2023

Targeted therapies for cholangiocarcinoma

Arndt Vogel • 22 Jul 2022

Related Videos

Novel developments in HCC treatment

Daneng Li • 6 Jul 2020

Regorafenib in refractory biliary tract cancer

Richard D. Kim • 3 Jul 2020

Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions

Milind Javle • 1 Jul 2020

The gut microbiome: role in causing and detecting colorectal cancer

Paul O'Toole • 29 Nov 2018